Samsung Bioepis Gets Its First Biosimilar Approval
This article was originally published in Scrip
Executive Summary
Within just three and a half years since its establishment, Samsung Bioepis has received its first regulatory approval for a biosimilar, meaning the Samsung Group affiliate is now set to release its version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) in South Korea late this year or early next. It will be the fourth locally developed biosimilar to hit the domestic market and is expected to be priced at about a 30% discount.